MLYS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Mineralys Therapeutics Inc (MLYS) is not a strong buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The technical indicators show a bearish trend, the financial performance is weak with declining net income and EPS, and there are no significant positive catalysts or trading signals to suggest immediate upside potential. It is better to hold off on investing at this time.
The MACD is below 0 and negatively expanding, indicating a bearish trend. RSI is neutral at 30.501, and moving averages are converging, showing no clear trend. The stock is trading near its S2 support level of 27.32, which could act as a potential floor, but overall, the technical indicators suggest weakness.
Hedge funds have significantly increased their buying activity by 516.79% over the last quarter. Analysts have raised price targets, with Stifel increasing to $52 and BofA to $46, maintaining a Buy rating. A potential catalyst could be finding a commercialization and development partner.
The stock has an 80% chance of declining in the next day, week, and month based on historical patterns. No significant insider or congress trading trends were observed.
In Q3 2025, the company reported no revenue growth, a net income decline of 34.45% YoY to -$36.93M, and a significant EPS drop of 53.98% YoY to -0.52. These figures indicate poor financial health and growth trends.
Analysts are optimistic about the stock, with Stifel raising the price target to $52 and BofA to $46, both maintaining Buy ratings. However, the optimism hinges on the company securing a commercialization and development partner, which is not guaranteed in the near term.
